SC
ELVN icon

Steven Cohen’s Enliven Therapeutics ELVN Stock Holding History

Steven Cohen’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,504,601
Closed -$41.7M – 3963
2025
Q4 		$23.2M Buy
1,504,601
+464,191
+45% +$9.25M 0.03% 790
2025
Q3 		$21.3M Sell
1,040,410
-312,668
-23% -$6.3M 0.04% 532
2025
Q2 		$27.1M Buy
1,353,078
+1,213,160
+867% +$23M 0.05% 397
2025
Q1 		$2.75M Buy
+139,918
New +$3.01M 0.01% 1143
2023
Q2 		– Sell
-746
Closed -$16.3K – 2324
2023
Q1 		$16.3K Buy
+746
New +$15.2K ﹤0.01% 1993

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Steven Cohen's ELVN Position: Q1 2026 in Review

Steven Cohen sold out of Enliven Therapeutics (ELVN) in Q1 2026, closing a stake of 1,504,601 shares — an estimated $41.7M sold.

Steven Cohen first reported a position in ELVN in Q1 2023 and held it in 5 quarters. The position peaked at $27.1M in Q2 2025. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Steven Cohen reported no remaining Enliven Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Steven Cohen sold 1,504,601 Enliven Therapeutics shares in Q1 2026, an estimated $41.7M.
  • Steven Cohen first reported a position in Enliven Therapeutics in Q1 2023 and held it in 5 quarters.
  • Steven Cohen's Enliven Therapeutics position peaked at $27.1M in Q2 2025.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.